Saturday 17 October 2026 Export VRPX’s income statement to Excel — free account

Virpax Pharmaceuticals, Inc.

In the quarter to December 2024, EPS grew 153.6% and free cash flow grew 4.68%, each against the same quarter a year earlier.

0.00 0.00 NaN

Follow VRPX

Alert me

Market cap: $160.0K
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.16

Revenue —

Net Income (12.07)

Free Cash Flow (16.71)

Net Debt (1.51)

Current Ratio 0.63

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 78.10%

Next Y EPS Growth 19.35%

Next Y revenue growth —

Next 5Y EPS Growth 42.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 40.17%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	2024
Cash	37	19	9	2
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	40	20	10	2

	2021	2022	2023	2024
Payables	2	1	2	2
ST’ Debt	—	—	—	—
Other	—	2	6	—
	2	3	8	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	(8)	(2)	(4)	(3)	(17)
’23	(2)	(2)	(3)	(3)	(10)
’22	(6)	(5)	(5)	(2)	(18)
’21	(3)	(2)	(5)	(5)	(15)
’20	0	0	(1)	0	(1)
’19	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	(8)	(2)	(4)	(3)	(17)
’23	(2)	(2)	(3)	(3)	(10)
’22	(6)	(5)	(5)	(2)	(18)
’21	(3)	(2)	(5)	(5)	(15)
’20	0	0	(1)	0	(1)
’19	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	(68.75)	(43.75)	(10.75)	52.23	(71.00)
’23	(32.50)	(67.50)	(127.50)	(97.37)	(324.25)
’22	(110.00)	(125.00)	(162.50)	(65.00)	(462.50)
’21	(150.00)	(117.50)	(132.50)	(48.75)	(452.50)
’20	(53.90)	(102.85)	(135.91)	(56.46)	(350.00)
’19	—	—	(0.20)	(0.13)	(282.22)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	—	—	—	—	—	777.50	152.50	60.05	7.15	Analyst estimates 2025–2027 Powerpack
	High	—	—	—	—	—	—	9,000.00	917.50	300.00	137.00
People
People	Employees	—	—	—	—	—	4	8	7	7	2
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	(3)	(3)	(4)	(12)	(22)	(15)	(12)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	0	(3)	(3)	(4)	(12)	(22)	(15)	(12)
	Depreciation	—	—	—	—	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.51)	(282.22)	(350.00)	(452.50)	(462.50)	(324.25)	(71.00)
	Cash flow	—	—	—	(0.35)	(96.73)	(111.69)	(544.67)	(381.34)	(210.55)	(98.20)
	Capex	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	(0.35)	(96.73)	(111.69)	(544.67)	(381.34)	(210.55)	(98.20)
	Book value	—	—	—	(0.23)	(233.53)	(340.01)	1,403.93	354.25	41.33	(5.37)
	Shares, m	—	—	—	5	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(2)	(1)	(1)	(15)	(18)	(10)	(17)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	—	—	—	(2)	(1)	(1)	(15)	(18)	(10)	(17)
Balance, $m
Balance, $m	Working capital	—	—	—	(1)	(3)	(4)	37	17	2	(1)
	Total debt	—	—	—	1	1	1	—	—	—	—
	Net debt	—	—	—	0	0	1	(37)	(19)	(9)	(2)
	Shareholders’ equity	—	—	—	(1)	(3)	(4)	37	17	2	(1)
Returns, %
Returns, %	ROA	—	—	—	(8,588.29)	(6,111.83)	(1,694.86)	(60.22)	(73.09)	(103.68)	(215.80)
	ROIC	—	—	—	0.00	0.00	0.00	(1,169.25)	0.00	0.00	0.00
	ROE	—	—	—	134.57	168.48	124.91	(72.48)	(80.09)	(164.09)	(2,364.96)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR	$640.0K	0.0×	— (loss-making)	—	n/m	+51.13% (above 0%: growing)	(228.63%)	(504.50%)	Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$440.0K	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
VINC Vincerx Pharma, Inc.	$250.0K	— (loss-making)	—	—	n/m	+42.45% (above 0%: growing)	0.00%	0.00%	Compare
CDT CDT Equity Inc.	$240.0K	— (loss-making)	—	—	n/m	+78.92% (above 0%: growing)	—	0.00%	Compare
EFTR eFFECTOR Therapeutics, Inc.	$200.0K	— (loss-making)	—	+58.08% (above 0%: growing)	n/m	+4.86% (above 0%: growing)	0.00%	0.00%	Compare
VRPX Virpax Pharmaceuticals, Inc.	$160.0K	— (loss-making)	—	—	n/m	+4.68% (above 0%: growing)	—	0.00%
CERO CERo Therapeutics Holdings, Inc.	$140.0K	0.0×	—	—	n/m	+49.65% (above 0%: growing)	—	0.00%	Compare
Median of peers	$345.0K	—	—	+11.90%	—	+46.05%	0.00%	0.00%